| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-664SS | |||
| Azide and BSA Free | NBP2-81007 | |||
| Conjugate | Catalog # | Availability | Size | Price |
|---|---|---|---|---|
| Biotin | BBA9 | |||
| Fluorescein | BBA20 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | BBA20 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | FAB3567P-100 | |||
| Carrier Free | FAB3567P-025 | |||
| Carrier Free | FAB3567F-100 | |||
| Carrier Free | FAB3567F-025 | |||
| Carrier Free | FAB3567A-100 | |||
| Carrier Free | FAB3567A-025 | |||
| Carrier Free | FAB3567N-100 | |||
| Carrier Free | FAB3567N-025 | |||
| Carrier Free | FAB3567C-100 | |||
| Carrier Free | FAB3567C-025 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-71663SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-47491SS | |||
| Azide and BSA Free | NBP2-81005 | |||
| Conjugate | Catalog # | Availability | Size | Price |
|---|---|---|---|---|
| Allophycocyanin | FAB6169A | |||
| Fluorescein | FAB6169F | |||
| Phycoerythrin | FAB6169P | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | FAB6169P | |||
| Carrier Free | FAB6169A | |||
| Carrier Free | FAB6169F | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-56585SS | |||
| Azide and BSA Free | NBP2-33232 | |||
| Azide and BSA Free | NBP2-33232-1mg | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-69753SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-2737-0.025mg | |||
![Immunohistochemistry: VEGF Antibody (VG1) - BSA Free [NB100-664] - HPG induces less VEGF production, less myofibroblast differentiation and lower macrophage activation. The expression of VEGF, alpha-SMA and MAC387 in the peritoneal tissue sections was examined using a routine immunohistochemical method. Data were a typical microscopic view of the peritoneal tissue sections in each group. a VEGF was detected using mouse monoclonal anti-VEGF antibody from Novus. Left graph a typical microscopic view, Dark brown stain VEGF-expressing cells (pointed by red arrows), Bv blood vessels, M muscle, black small bar 10 um. Right graph VEGF-expressing cells per 200 um PM length in cross sections. Data were presented as mean +/- SD (n = 6) and were analyzed using t test. Image collected and cropped by CiteAb from the following publication (//translational-medicine.biomedcentral.com/articles/10.1186/s12967-016-1098-z) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/VEGF-Antibody-VG1-BSA-Free-Immunohistochemistry-NB100-664-img0015.jpg)
![Western Blot: VEGF Antibody (VG1) - BSA Free [NB100-664] - Regorafenib transcriptionally inhibited VEGF-A expression through decreasing binding of STAT3 on promoter of VEGF-A.(A) Top, MDA-MB-231 cells co-transfected w/ a Renilla control vector & plasmids containing firefly luciferase gene driven by wild-type or STAT3 binding site-mutated VEGF-A promoter. After transfection for 48 h, cells treated w/ regorafenib for 24 h. Promoter activity analyzed by luciferase assay after regorafenib treatment. Bottom, MDA-MB-231 cells transfected w/ vector-control or STAT3-overexpression plasmid for 48 h. After , cells further co-transfected w/ Renilla & wild-type VEGF-A promoter & detect promoter activity as mentioned above. *p < 0.05, **p < 0.01. (B) After regorafenib treatment for 24 h, STAT3 binding site fragment detected by PCR in ChIP samples precipitated w/ STAT3 & rabbit IgG control antibodies in MDA-MB-231 cells. (C,D), MDA-MB-231 cells transfected, respectively, w/ control vector or VEGF-A overexpression plasmid (C) or STAT3 overexpression plasmid (D) for 48 h. After transfection, cells treated w/wo regorafenib for 24 h & subjected to WB assay or seeded to Transwell to analyze migration ability. *p < 0.05, **p < 0.01. (E) Cells treated w/ regorafenib at indicated dosages for 24 h & cell lysates analyzed by SHP-1 phosphatase activity assay. *p < 0.05, **p < 0.01. (F) MDA-MB-231 cells pretreated w/ pan-phosphatase inhibitor (left), or specific SHP-1 inhibitor (Middle) for 1 h before regorafenib treatment. Right, MDA-MB-231 cells transfected, respectively, w/ control siRNA or SHP-1 siRNA for 48 h. After transfection, cells treated w/wo regorafenib (10 μM) for 24 h. The protein levels analyzed by WB assay or cells seeded to Transwell to analyze migration ability. *p < 0.05, **p < 0.01. Image collected & cropped by CiteAb from following publication (//pubmed.ncbi.nlm.nih.gov/27364975), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-664_mouse-monoclonal-vegf-antibody-vg1-31020241682159.jpg)
![Immunocytochemistry/Immunofluorescence: CD31/PECAM-1 Antibody [NBP1-71663] - Staining of mouse glioma tissue using CD31/PECAM-1 Antibody (NBP1-71663) at a dilution of 1:2500. Image provided by Dr. Eric Woolf of Dignity Health.](http://images.novusbio.com/fullsize/CD31-PECAM-1-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-71663-img0009.jpg "Immunocytochemistry/Immunofluorescence: CD31/PECAM-1 Antibody [NBP1-71663] - Staining of mouse glioma tissue using CD31/PECAM-1 Antibody (NBP1-71663) at a dilution of 1:2500. Image provided by Dr. Eric Woolf of Dignity Health.")
![Simple Western: CD31/PECAM-1 Antibody [NBP1-71663] - Image shows a specific band for CD31/PECAM 1 in 0.5 mg/mL of HUVEC lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/CD31-PECAM-1-Antibody-Simple-Western-NBP1-71663-img0010.jpg)
![<b>Biological Strategies Validation. </b>Immunohistochemistry: CD31/PECAM-1 Antibody [NBP1-71663] - 5-HTR1A agonist enhances neovascularization during skin wound healing (excisional punch biopsy model). CD31/PECAM-1 endothelial cell immunohistochemical staining at day 5 (A,B) and day 7 (E,F), image scale bars represented at 50 um. Results were presented as mean +/- SEM (n = 5 images per wound). Two-way ANOVA was performed and significance levels were set at *P < 0.05, **P < 0.01. Image collected and cropped by CiteAb from the following publication (//www.frontiersin.org/article/10.3389/fphar.2018.01406/full), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CD31-PECAM-1-Antibody-Immunohistochemistry-NBP1-71663-img0012.jpg)
![Western Blot: CD31/PECAM-1 Antibody [NBP1-71663] - Snail and EndMT-related protein expression in lungs in orthotopic murine 4T1 breast cancer model. ag Expression of Snail (see Methods). Levels of CD31/PECAM-1 determined by western blot analysis in pooled (n = 6) samples in control and 4T1 breast cancer-bearing mice from the 1st to 5th week after 4T1 cancer cell inoculation (see Methods). Results presented as fold change vs control sample corresponding to healthy mice. Total protein after transfer was used as loading control Image collected and cropped by Citeab from the following publication (Nitric oxide deficiency and endothelial-mesenchymal transition of pulmonary endothelium in the progression of 4T1 metastatic breast cancer in mice. Breast Cancer Res (2018) licensed under a CC-BY license](http://images.novusbio.com/fullsize/CD31-PECAM-1-Antibody-Western-Blot-NBP1-71663-img0013.jpg)
![Immunocytochemistry/Immunofluorescence: CD31/PECAM-1 Antibody [NBP1-71663] - HUVEC cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X TBS + 0.5% Triton X-100. The cells were incubated with CD31/PECAM-1 Antibody at 5 ug/mL overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at a 1:500 dilution. Alpha tubulin (DM1A) NB100-690 was used as a co-stain at a 1:1000 dilution and detected with an anti-mouse Dylight 550 (Red) at a 1:500 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/CD31-PECAM-1-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-71663-img0011.jpg)
![Flow Cytometry: CD31/PECAM-1 Antibody [NBP1-71663] - CD31/PECAM-1 Antibody was tested in WeHi cells with Dylight 488 (green) alongside a matched isotype control (black).](http://images.novusbio.com/fullsize/CD31-PECAM-1-Antibody-Flow-Cytometry-NBP1-71663-img0005.jpg)
![Western Blot: CD31/PECAM-1 Antibody [NBP1-71663] - Detection of CD31 in HUVEC cell lysates.](http://images.novusbio.com/fullsize/CD31-PECAM-1-Antibody-Western-Blot-NBP1-71663-img0008.jpg)
![Western Blot: VCAM-1/CD106 Antibody (6G9) [NBP1-47491] - Using VCAM1 mouse mAb against (1) HUVEC and (2) EC cell lysate.](http://images.novusbio.com/fullsize/VCAM-1-CD106-Antibody-6G9-Western-Blot-NBP1-47491-img0006.jpg "Western Blot: VCAM-1/CD106 Antibody (6G9) [NBP1-47491] - Using VCAM1 mouse mAb against (1) HUVEC and (2) EC cell lysate.")
![Immunohistochemistry: VCAM-1/CD106 Antibody (6G9) [NBP1-47491] - Photomicrographs of two separate gut sections from a patient with EHEC colitis. Panels (C) and (D) are stained to show VCAM-1/CD106 expression in endothelium, indicating inflammatory activation (40x magnification). Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0055278), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/VCAM-1-CD106-Antibody-6G9-Immunohistochemistry-NBP1-47491-img0010.jpg)
![Immunohistochemistry-Paraffin: VCAM-1/CD106 Antibody (6G9) [NBP1-47491] - (A) human lung cancer and (B) colon cancer using VCAM1 mouse mAb with DAB staining.](http://images.novusbio.com/fullsize/VCAM-1-CD106-Antibody-6G9-Immunohistochemistry-Paraffin-NBP1-47491-img0004.jpg)
![Immunohistochemistry-Paraffin: VCAM-1/CD106 Antibody (6G9) [NBP1-47491] - Human placenta tissues using VCAM1 mouse mAb.](http://images.novusbio.com/fullsize/VCAM-1-CD106-Antibody-6G9-Immunohistochemistry-Paraffin-NBP1-47491-img0005.jpg)
![Immunohistochemistry: VCAM-1/CD106 Antibody (6G9) [NBP1-47491] - Breast carcinoma, cytoplasmic staining. IHC image submitted by a verified customer review.](http://images.novusbio.com/fullsize/VCAM-1-CD106-Antibody-6G9-Immunohistochemistry-NBP1-47491-img0007.jpg)
![Immunohistochemistry-Paraffin: VCAM-1/CD106 Antibody (6G9) [NBP1-47491] - FFPE section of human lung cancer. Image at 20X magnification. IHC-P image submitted by a verified customer review.](http://images.novusbio.com/fullsize/VCAM-1-CD106-Antibody-6G9-Immunohistochemistry-Paraffin-NBP1-47491-img0009.jpg)
![Simple Western: VCAM-1/CD106 Antibody (6G9) [NBP1-47491] - Lane view shows a specific band for CD106/VCAM1 in 0.5 mg/mL of HUVEC lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/VCAM-1-CD106-Antibody-6G9-Simple-Western-NBP1-47491-img0008.jpg)
![Immunocytochemistry/ Immunofluorescence: VCAM-1/CD106 Antibody (6G9) - BSA Free [NBP1-47491] - Enhanced expression of endothelial SENP1 & GATA2 correlates w/ graft arteriosclerosis (GA) progression.Similarly sized human coronary arteries w/ GA from chronically rejecting heart allografts or w/out disease from non-transplanted hearts collected & evaluated by histological analysis. (a,b) Dramatically increased expression of endothelial SENP1 detected in the diseased vessel wall. Endothelial SENP1 expression is demonstrated by immunofluorescence analysis of coronary artery cross-sections that stained for SENP1 & the endothelial marker PECAM-1 w/ DAPI labelling of the nuclei. Representative images are shown in (a) w/ quantification data in (b). Bar represents 50 μm. (c) Induction of endothelial adhesion molecules resulted in a similar augmented pattern as endothelial SENP1. Representative images of immunofluorescence staining for VCAM-1 or P-selectin & PECAM-1 in coronary arteries w/ DAPI counterstaining are shown. Bar represents 50 μm. (d,e) Expression of endothelial GATA2 elevated w/ the progression of aggravated rejection. Representative images of the immunofluorescence staining of coronary arteries for GATA2 & PECAM-1 together w/ DAPI nuclear staining are shown in (d) w/ quantification data in (e). Negative SENP1 & GATA2 staining in the isotype or blocking peptide controls are also shown in (a) & (d). Bar represents 50 μm. Data presented in (b,e) are the mean±s.e.m. from five separate clinical specimens per group as indicated. *P<0.05, **P<0.01 & ***P<0.0001; one-way ANOVA followed by Bonferroni test. GA, graft arteriosclerosis; PECAM, platelet/endothelial cell adhesion molecule; SENP, sentrin-specific protease; VCAM, vascular cell adhesion molecule. Image collected & cropped by CiteAb from the following publication (//www.nature.com/articles/ncomms15426), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-47491_mouse-monoclonal-vcam-1-cd106-antibody-6g9-310202416161834.jpg)
![Immunocytochemistry/ Immunofluorescence: VCAM-1/CD106 Antibody (6G9) - BSA Free [NBP1-47491] - Loss of endothelial SENP1 inhibits EC activation.(a) Grafts from WT or SENP1-ecKO mice were harvested 3 days post-transplantation. The induction of endothelial adhesion molecules was demonstrated by immunofluorescence staining of ICAM-1, VCAM-1, or P-selectin & PECAM-1 with DAPI labelling of the nuclei. Bar represents 50 μm. (b–e) Attenuated induction of adhesion molecules in SENP1-ecKO MAECs. Flow cytometry analysis of ICAM-1, VCAM-1 & P-selectin in MAECs isolated from WT or SENP1-ecKO mice after TNF or IL-1 beta treatment. Representative histograms are shown in (b) with the quantification of mean intensity in (c–e). (f–h) Overexpression of the catalytically inactive form of SENP1 (SENP1-Mut) inhibits the induction of adhesion molecules in HUVECs. HUVECs were infected by Ad-SENP1-Mut or vector control (Ad-LacZ) for 24 h, treated with pro-inflammatory cytokines & analysed by flow cytometry in the same way as MAECs. Representative histograms of ICAM-1 & VCAM-1 are shown in (f) with the quantification of mean intensity in (g,h). Data are presented as the mean±s.e.m. from at least three independent experiments. *P<0.05 & **P<0.01; two-way ANOVA followed by Bonferroni post-test. MAEC, mouse aortic endothelial cell. Image collected & cropped by CiteAb from the following publication (//www.nature.com/articles/ncomms15426), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-47491_mouse-monoclonal-vcam-1-cd106-antibody-6g9-31020241616185.jpg)
![Western Blot: TEM8/ANTXR1 Antibody (200C1339(SB20)) [NB100-56585] - Detection in TEM8 transfected cell lysate using this antibody.](http://images.novusbio.com/fullsize/TEM8-ANTXR1-Antibody-200C1339-SB20-Western-Blot-NB100-56585-img0018.jpg "Western Blot: TEM8/ANTXR1 Antibody (200C1339(SB20)) [NB100-56585] - Detection in TEM8 transfected cell lysate using this antibody.")
![Immunohistochemistry-Paraffin: TEM8/ANTXR1 Antibody (200C1339(SB20)) [NB100-56585] - Detection of TEM8/ANTXR1 in human liver cancer section using 5 ug/ml concentration of TEM8 antibody. Uniform weak staining was observed in the cancerous cells, while the blood vessels depicted the expected intense positivity for TEM8.](http://images.novusbio.com/fullsize/TEM8-ANTXR1-Antibody-200C1339-SB20-Immunohistochemistry-Paraffin-NB100-56585-img0016.jpg)
![Western Blot: TEM8/ANTXR1 Antibody (200C1339(SB20)) [NB100-56585] - Analysis of human heart lysates (35ug per lane, RIPA buffer) using TEM8 antibody (NB100-56585) at 0.3ug/ml. Band observed at 65kDa. (Expected MW of 62.8kDa according to NP_115584.1).](http://images.novusbio.com/fullsize/TEM8-ANTXR1-Antibody-200C1339-SB20-Western-Blot-NB100-56585-img0017.jpg)
![Immunohistochemistry-Paraffin: TEM8/ANTXR1 Antibody (200C1339(SB20)) [NB100-56585] - Human colon stained with TEM8 antibody at 2.5 ug/ml concentration using DAB chromogen detection method (10X magnification)](http://images.novusbio.com/fullsize/TEM8-ANTXR1-Antibody-200C1339-SB20-Immunohistochemistry-Paraffin-NB100-56585-img0015.jpg)
![Western Blot: Tie-2 Antibody [NBP1-69753] - Total protein from human Huvec cells and mouse stomach tissue was separated on a 7.5% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 1.0 ug/ml anti-TIE2 in 1% non-fat milk in TBST and detected with an anti-rabbit HRP secondary antibody using chemiluminescence.](http://images.novusbio.com/fullsize/Tie-2-Antibody-Western-Blot-NBP1-69753-img0006.jpg "Western Blot: Tie-2 Antibody [NBP1-69753] - Total protein from human Huvec cells and mouse stomach tissue was separated on a 7.5% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 1.0 ug/ml anti-TIE2 in 1% non-fat milk in TBST and detected with an anti-rabbit HRP secondary antibody using chemiluminescence.")
![Immunohistochemistry-Paraffin: Tie-2 Antibody [NBP1-69753] - Analysis of a FFPE tissue section of mouse stomach using 1:200 dilution of Tie-2 antibody (NBP1-69753). The staining was developed using HRP labeled anti-rabbit secondary antibody and DAB reagent, and nuclei of cells were counter-stained with hematoxylin.](http://images.novusbio.com/fullsize/Tie-2-Antibody-Immunohistochemistry-Paraffin-NBP1-69753-img0007.jpg)
![Western Blot: Tie-2 Antibody [NBP1-69753] - Detection of TIE2 in Huvec cell lysate](http://images.novusbio.com/fullsize/Tie-2-Antibody-Western-Blot-NBP1-69753-img0003.jpg)
![Simple Western: Tie-2 Antibody [NBP1-69753] - Simple Western lane view shows a specific band for Tie-2 in 0.5 mg/ml of HUVEC lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/Tie-2-Antibody-Simple-Western-NBP1-69753-img0005.jpg)
![Immunohistochemistry: PD-ECGF/Thymidine Phosphorylase Antibody (PGF 44C) [NB100-2737] - Immunohistochemical staining of thymidine phosphorylase (TP) expression and related markers in benign lymph node. In benign lymph node, TP expression highlights the meshwork of macrophages (arrow in inset; 400x) and endothelial cells (arrowhead in inset; 400x). Images are from an Olympus BX41 microscope (Olympus Corp., Tokyo, Japan) processed with Qcapture Pro 5.1 (QImaging, Surrey, BC, Canada). Image collected and cropped by CiteAb from the following publication (//www.hindawi.com/journals/ah/2011/875135/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/PD-ECGF-Thymidine-Phosphorylase-Antibody-PGF-44C-Immunohistochemistry-NB100-2737-img0003.jpg "Immunohistochemistry: PD-ECGF/Thymidine Phosphorylase Antibody (PGF 44C) [NB100-2737] - Immunohistochemical staining of thymidine phosphorylase (TP) expression and related markers in benign lymph node. In benign lymph node, TP expression highlights the meshwork of macrophages (arrow in inset; 400x) and endothelial cells (arrowhead in inset; 400x). Images are from an Olympus BX41 microscope (Olympus Corp., Tokyo, Japan) processed with Qcapture Pro 5.1 (QImaging, Surrey, BC, Canada). Image collected and cropped by CiteAb from the following publication (//www.hindawi.com/journals/ah/2011/875135/) licensed under a CC-BY license.")
![Immunohistochemistry: PD-ECGF/Thymidine Phosphorylase Antibody (PGF 44C) [NB100-2737] - Immunohistochemical staining of thymidine phosphorylase (TP) expression and related markers in benign lymph node in lymph node with malignant mycosis fungoides/Sezary syndrome cells (LN-MF). CD21 is negative in this case of LN-MF. Images are from an Olympus BX41 microscope (Olympus Corp., Tokyo, Japan) processed with Qcapture Pro 5.1 (QImaging, Surrey, BC, Canada). Image collected and cropped by CiteAb from the following publication (//www.hindawi.com/journals/ah/2011/875135/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/PD-ECGF-Thymidine-Phosphorylase-Antibody-PGF-44C-Immunohistochemistry-NB100-2737-img0008.jpg)
![Immunohistochemistry: PD-ECGF/Thymidine Phosphorylase Antibody (PGF 44C) [NB100-2737] - Immunohistochemical staining of thymidine phosphorylase (TP) expression and related markers in benign lymph node in lymph node with malignant mycosis fungoides/Sezary syndrome cells (LN-MF). LN-MF: hematoxylin and eosin (H&E) stain. Images are from an Olympus BX41 microscope (Olympus Corp., Tokyo, Japan) processed with Qcapture Pro 5.1 (QImaging, Surrey, BC, Canada). Image collected and cropped by CiteAb from the following publication (//www.hindawi.com/journals/ah/2011/875135/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/PD-ECGF-Thymidine-Phosphorylase-Antibody-PGF-44C-Immunohistochemistry-NB100-2737-img0004.jpg)
![Immunohistochemistry: PD-ECGF/Thymidine Phosphorylase Antibody (PGF 44C) [NB100-2737] - Immunohistochemical staining of thymidine phosphorylase (TP) expression and related markers in benign lymph node in lymph node with malignant mycosis fungoides/Sezary syndrome cells (LN-MF). CD3 highlights the malignant T cells and reactive T cells in LN-MF. Images are from an Olympus BX41 microscope (Olympus Corp., Tokyo, Japan) processed with Qcapture Pro 5.1 (QImaging, Surrey, BC, Canada). Image collected and cropped by CiteAb from the following publication (//www.hindawi.com/journals/ah/2011/875135/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/PD-ECGF-Thymidine-Phosphorylase-Antibody-PGF-44C-Immunohistochemistry-NB100-2737-img0005.jpg)
![Immunohistochemistry: PD-ECGF/Thymidine Phosphorylase Antibody (PGF 44C) [NB100-2737] - Immunohistochemical staining of thymidine phosphorylase (TP) expression and related markers in benign lymph node in lymph node with malignant mycosis fungoides/Sezary syndrome cells (LN-MF). CD4 is weakly expressed in the malignant T cells in LN-MF. Images are from an Olympus BX41 microscope (Olympus Corp., Tokyo, Japan) processed with Qcapture Pro 5.1 (QImaging, Surrey, BC, Canada). Image collected and cropped by CiteAb from the following publication (//www.hindawi.com/journals/ah/2011/875135/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/PD-ECGF-Thymidine-Phosphorylase-Antibody-PGF-44C-Immunohistochemistry-NB100-2737-img0006.jpg)
![Immunohistochemistry: PD-ECGF/Thymidine Phosphorylase Antibody (PGF 44C) [NB100-2737] - Immunohistochemical staining of thymidine phosphorylase (TP) expression and related markers in benign lymph node in lymph node with malignant mycosis fungoides/Sezary syndrome cells (LN-MF). CD68 highlights the macrophages in LN-MF. Images are from an Olympus BX41 microscope (Olympus Corp., Tokyo, Japan) processed with Qcapture Pro 5.1 (QImaging, Surrey, BC, Canada). Image collected and cropped by CiteAb from the following publication (//www.hindawi.com/journals/ah/2011/875135/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/PD-ECGF-Thymidine-Phosphorylase-Antibody-PGF-44C-Immunohistochemistry-NB100-2737-img0007.jpg)
![Immunohistochemistry: PD-ECGF/Thymidine Phosphorylase Antibody (PGF 44C) [NB100-2737] - Immunohistochemical staining of thymidine phosphorylase (TP) expression and related markers in benign lymph node in lymph node with malignant mycosis fungoides/Sezary syndrome cells (LN-MF). TP highlights the macrophages (cytoplasmic/nuclear pattern, arrowhead in inset 1; 400x) and the malignant T cells (cytoplasmic pattern, arrow in inset 2; 400x) in a cytoplasmic staining pattern. Multiple mitotic figures are also noted in the malignant T cells. Images are from an Olympus BX41 microscope (Olympus Corp., Tokyo, Japan) processed with Qcapture Pro 5.1 (QImaging, Surrey, BC, Canada). Image collected and cropped by CiteAb from the following publication (//www.hindawi.com/journals/ah/2011/875135/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/PD-ECGF-Thymidine-Phosphorylase-Antibody-PGF-44C-Immunohistochemistry-NB100-2737-img0009.jpg)